NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $11.81 -0.26 (-2.15 %) (As of 07/20/2018 04:00 PM ET)Previous Close$12.07Today's Range$11.58 - $12.1052-Week Range$6.30 - $24.38Volume110,294 shsAverage Volume215,069 shsMarket Capitalization$405.60 millionP/E Ratio-5.55Dividend YieldN/ABeta-2.57 Company ProfileAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts. Receive SYRS News and Ratings via Email Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:SYRS CUSIPN/A Webwww.syros.com Phone617-744-1340 Debt Debt-to-Equity RatioN/A Current Ratio5.78 Quick Ratio5.78 Price-To-Earnings Trailing P/E Ratio-5.55 Forward P/E Ratio-5.37 P/E GrowthN/A Sales & Book Value Annual Sales$1.10 million Price / Sales349.79 Cash FlowN/A Price / CashN/A Book Value$2.40 per share Price / Book4.92 Profitability EPS (Most Recent Fiscal Year)($2.13) Net Income$-54,010,000.00 Net MarginsN/A Return on Equity-67.11% Return on Assets-57.78% Miscellaneous Employees56 Outstanding Shares32,580,000Market Cap$405.60 Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions What is Syros Pharmaceuticals' stock symbol? Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS." How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals Inc (NASDAQ:SYRS) released its quarterly earnings results on Monday, March, 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.01. View Syros Pharmaceuticals' Earnings History. When is Syros Pharmaceuticals' next earnings date? Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Syros Pharmaceuticals. What price target have analysts set for SYRS? 8 brokers have issued 1-year price targets for Syros Pharmaceuticals' shares. Their predictions range from $10.00 to $33.00. On average, they anticipate Syros Pharmaceuticals' share price to reach $22.4286 in the next year. This suggests a possible upside of 89.9% from the stock's current price. View Analyst Ratings for Syros Pharmaceuticals. What is the consensus analysts' recommendation for Syros Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Syros Pharmaceuticals stock? Here are some recent quotes from research analysts about Syros Pharmaceuticals stock: 1. According to Zacks Investment Research, "Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. " (7/17/2018) 2. Cann analysts commented, "For 2018 we have adjusted revenue to account for a $10 million upfront payment being carried on the balance sheet rather than being recognized as revenue this year; and we are fine-tuning estimated operating expenses and estimated shares outstanding. As a result, our estimated loss per share is being increased to $2.04 from our prior estimated loss of $1.81. Our estimated revenue and net income for 2019-22 is unchanged. Estimated loss per share is being increased by $0.01 per year in years 2019 and 2020 as a result of slightly reduced estimated shares outstanding." (5/10/2018) Who are some of Syros Pharmaceuticals' key competitors? Some companies that are related to Syros Pharmaceuticals include IMMURON Ltd/S (IMRN), Corcept Therapeutics (CORT), G1 Therapeutics (GTHX), ARMO Biosciences (ARMO), Pacira Pharmaceuticals (PCRX), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Biohaven Pharmaceutical (BHVN), Innoviva (INVA), TherapeuticsMD (TXMD), Deciphera Pharmaceuticals (DCPH), Theravance Biopharma (TBPH), Lexicon Pharmaceuticals (LXRX), Amneal Pharmaceuticals (AMRX) and Impax Laboratories (IPXL). Who are Syros Pharmaceuticals' key executives? Syros Pharmaceuticals' management team includes the folowing people: Dr. Nancy A. Simonian, Pres, CEO & Director (Age 57)Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 64)Dr. David A. Roth, Chief Medical Officer (Age 55)Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 56)Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board When did Syros Pharmaceuticals IPO? (SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Has Syros Pharmaceuticals been receiving favorable news coverage? Headlines about SYRS stock have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a news impact score of 0.16 on Accern's scale. They also assigned news articles about the company an impact score of 46.25 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Syros Pharmaceuticals' stock price today? One share of SYRS stock can currently be purchased for approximately $11.81. How big of a company is Syros Pharmaceuticals? Syros Pharmaceuticals has a market capitalization of $405.60 million and generates $1.10 million in revenue each year. The company earns $-54,010,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Syros Pharmaceuticals employs 56 workers across the globe. How can I contact Syros Pharmaceuticals? Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected] MarketBeat Community Rating for Syros Pharmaceuticals (NASDAQ SYRS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 188 (Vote Outperform)Underperform Votes: 156 (Vote Underperform)Total Votes: 344MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: Are Wall Street analysts' stock ratings worth following?